Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0198 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Chuan Liu und 41 weiteren Autor:innen. Beteiligte Einrichtung: Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast Uni…. Hauptthemen laut MEDLINE: Carbazoles, Carvedilol, Hypertension, Portal, Liver Cirrhosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Science and Technology Innovation 2030 Major Program, The Key Research and Development Program of Jiangsu Province, Fundamental Research Fund of Southeast University.
Abstract (Originalsprache)
Backgrounds/Aims: Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol can prevent hepatic decompensation in patients with high-risk CSPH stratified using the new model.
Methods
Non-invasive risk factors of CSPH were identified via systematic review and meta-analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new non-invasive model was validated for various performance aspects in three cohorts, i.e., a multicenter HVPG cohort, a follow-up cohort, and a carvediloltreating cohort.
Results
In the meta-analysis with six studies (n=819), liver stiffness measurement and platelet count were identified as independent risk factors for CSPH and were used to develop the new “CSPH risk” model. In the HVPG cohort (n=151), the new model accurately predicted CSPH with cutoff values of 0 and –0.68 for ruling in and out CSPH, respectively. In the follow-up cohort (n=1,102), the cumulative incidences of decompensation events significantly differed using the cutoff values of 0 (high-risk). In the carvediloltreated cohort, patients with high-risk CSPH treated with carvedilol (n=81) had lower rates of decompensation events than non-selective beta-blockers untreated patients with high-risk CSPH (n=613 before propensity score matching [PSM], n=162 after PSM).
Conclusions
Treatment with carvedilol significantly reduces the risk of hepatic decompensation in patients with high-risk CSPH stratified by the new model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of…
- Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University; State Key Laboratory of Digital Medical Engineering, Nanjing, China.
- Liver Research Center, Beijing Friendship Hospital, Capital Medical University, State Key Lab of Digestive Health, National Clinical Research Center of Digestive Diseases, Beijing, China.
- Department of Infectious Diseases and Hepatology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Gastroenterology & Hepatology, Changi General Hospital, Singapore.
- Duke-NUS Medical School, Singapore.
Förderung
- National Science and Technology Innovation 2030 Major Program
- The Key Research and Development Program of Jiangsu Province
- Fundamental Research Fund of Southeast University
- Changjiang Scholars Talent Cultivation Project of Zhongda Hospital of Southeast University
- Research Personnel Cultivation Programme of Zhongda Hospital Southeast University
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Liu, C., You, H., Zeng, Q. L., Wong, Y. J., Wang, B., Grgurevic, I., Liu, C., Yim, H. J., Gou, W., Dong, B., Ju, S., Guo, Y., Yu, Q., Hirooka, M., Enomoto, H., Hanafy, A. S., Cao, Z., Dong, X., Lv, J., …, & Qi, X. (2025). Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306). Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0198
Vancouver
Liu C, You H, Zeng QL, Wong YJ, Wang B, Grgurevic I, et al. Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306). Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0198
BibTeX
@article{Liu2025,
author = {Liu, Chuan and You, Hong and Zeng, Qing-Lei and Wong, Yu Jun and Wang, Bingqiong and Grgurevic, Ivica and Liu, Chenghai and Yim, Hyung Joon and Gou, Wei and Dong, Bingtian and Ju, Shenghong and Guo, Yanan and Yu, Qian and Hirooka, Masashi and Enomoto, Hirayuki and Hanafy, Amr Shaaban and Cao, Zhujun and Dong, Xiemin and Lv, Jing and Kim, Tae Hyung and Koizumi, Yohei and Hiasa, Yoichi and Nishimura, Takashi and Iijima, Hiroko and Xu, Chuanjun and Dai, Erhei and Lan, Xiaoling and Lai, Changxiang and Liu, Shirong and Wang, Fang and Guo, Ying and Lv, Jiaojian and Zhang, Liting and Wang, Yuqing and Xie, Qing and Shao, Chuxiao and Liu, Zhensheng and Ravaioli, Federico and Colecchia, Antonio and Li, Jie and Teng, Gao-Jun and Qi, Xiaolong},
title = {Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0198}
}
EUVIMED